Income Statement
MEREO BIOPHARMA GROUP PLC
MREO
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Revenue
|
0.50 | 0.00 | 10.00 |
|
Cost of Revenue
|
- | - | - |
|
Gross Profit
|
0.50 | - | 10.00 |
|
Operating Expenses
|
40.77 | 47.36 | 35.84 |
|
Research & Development
|
17.77 | 20.93 | 17.42 |
|
Selling, General & Administrative
|
23.01 | 26.43 | 18.42 |
|
Other Operating Expenses
|
- | - | - |
|
Operating Income
|
-40.27 | -47.36 | -25.84 |
|
Non-Operating Income
|
1.60 | -4.11 | 4.16 |
|
Interest Income
|
2.17 | 3.04 | 2.13 |
|
Interest Expense
|
0.26 | 1.37 | 2.88 |
|
Other Non-Op Income / Expense
|
0.30 | 0.00 | -0.01 |
|
Income Before Tax
|
-41.88 | -43.25 | -30.00 |
|
Income Tax Expense
|
0.00 | 0.00 | -0.53 |
|
Non-Controlling Interest
|
- | - | - |
|
Net Income
|
-41.88 | -43.25 | -29.47 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - |
|
EBITDA
|
-40.27 | -47.36 | -25.84 |
|
Earnings Per Share (Basic)
|
-0.05 | -0.06 | -0.04 |
|
Diluted EPS
|
-0.05 | -0.06 | -0.04 |
|
Weighted Average Shares
|
797.12 | 739.62 | 659.45 |
|
Diluted Weighted Avg Shares
|
797.12 | 739.62 | 659.45 |
|
Comprehensive Income
|
-33.85 | -44.62 | -25.26 |